Asahi Kasei Corporation
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Koshiro Kudo
- Full Time Employees
- 47,895
- Sector
- Industrials
- Industry
- Conglomerates
- Address
- Hibiya Mitsui Tower Tokyo TY Japan 100-0006
- IPO Date
- Jun 7, 2002
- Website
- asahi-kasei.com
- Similar Companies
- Business
- Asahi Kasei Corp. (AHKSF) manufactures and markets a broad portfolio of chemicals, materials, homes, and healthcare products worldwide. Founded in 1931 and headquartered in Tokyo, Japan, the company operates through three primary sectors: Materials, which encompasses basic chemicals such as acrylonitrile, ethylene, and caustic soda; performance products including high-performance resins like LEONA polyamide and TENAC polyacetal, fibers, electronics materials such as photosensitive polyimides and semiconductor components, clean energy materials, and optical materials; Homes, centered on Hebel Haus unit homes, Hebel autoclaved aerated concrete panels, Neoma Foam phenolic foam insulation, foundation systems, and steel-frame structural components along with remodeling and real estate services; and Healthcare, featuring medical devices for blood purification and transfusion including Planova virus removal filters and leukocyte reduction filters, bioprocess products, critical care solutions such as defibrillators, automated CPR systems, and temperature management devices, pharmaceuticals in orthopedics and urology, and diagnostic reagents. The company serves diverse markets including automotive, construction, electronics, medical, and consumer sectors across Japan, Asia, Europe, North America, South America, and Oceania. In late 2025, Asahi Kasei entered an absorption-type merger agreement with Teijin Ltd. to integrate its wholly owned subsidiary Asahi Kasei Advance Corp. with Teijin Frontier Co. Ltd., creating a joint venture owned 20% by Asahi Kasei and 80% by Teijin effective October 1, 2026, aimed at combining textile and materials distribution platforms for sustainable growth; earlier in 2024, it announced the acquisition of Calliditas Therapeutics AB to bolster its global pharmaceuticals capabilities; and as part of its "Trailblaze Together" medium-term plan, it exited the methyl methacrylate monomer business while expanding capacity for photosensitive polyimides to prioritize high-growth areas in healthcare, critical care, and semiconductor materials.
Company News
Asahi Kasei Microdevices' CZ39 and CZ3K Current Sensors Featured in Microchip Technology's Machine Learning-Based Arc Fault Detection Reference Design
Asahi Kasei Unveils New Wet-Process Separator Coating Line in North Carolina, Advancing the Company's 40-Year North American Battery Separator Strategy
Asahi Kasei Develops Novel Lithium Pre-doping Technology to Raise Energy Density and Lower Cost of Silicon-rich Lithium-ion Batteries
Asahi Kasei's Capacity Expansion for Water Electrolysis and Chlor‑Alkali Equipment in Kawasaki Awarded Regional Economic Incentives
Asahi Kasei Enters First License Agreement for Production and Sale of Acetolyte™ Novel Electrolyte in China
Asahi Kasei's Novel Forward Osmosis–Membrane Distillation System Installed at Peptistar's API Manufacturing Facility for Reduced Pharmaceutical Manufacturing Time
Asahi Kasei Develops Novel Photosensitive Polyimide Film for Advanced Panel-Level Semiconductor Packaging
Asahi Kasei Optimizes Material Portfolio Through Supply Realignment by FY2030
Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy
Chevron Technology Ventures, Asahi Kasei Invest in Heavy-Industry Robotics Company KEWAZO
Asahi Kasei Begins Installation of Containerized Alkaline-Water Electrolyzer at Finland's First Commercial Hydrogen Refueling Station
Asahi Kasei Strengthens Global Pharmaceutical Platform with the Acquisition of Aicuris
Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead Compounds
Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory Diseases
Asahi Kasei Develops PFAS-Free PA66 Offering Low-Friction and High-Load Performance
ZOLL Strengthens Growth Trajectory for Asahi Kasei's Healthcare Sector with U.S. Launch of the Next-Generation LifeVest® WCD and Rollout of the Most Comfortable LifeVest Garment Ever, Reinforcing Position as Leader in WCD Category
Asahi Kasei Pharma to Relocate Global R&D Hub to Shonan iPark
Asahi Kasei Microdevices and Aizip Deliver Transformative AI-Enhanced Sensing Solutions
Asahi Kasei Receives 2025 TSMC Excellent Performance Award in Recognition of Its PIMEL™ Photosensitive Dielectric for Advanced Packaging Material
Asahi Kasei Strengthens Long-Term Profitability by Phasing Out HMD Production as Part of Structural Reform